Ángel Juan García-Yagüe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ángel Juan García-Yagüe has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Cuadrado
Department of Biochemistry, School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain
14 shared publications - Isabel Lastres-Becker
Instituto de Investigaciones Biomédicas “Sols-Morreale” CSIC-UAM, Spain
7 shared publications Ana I. Rojo
Department of Biochemistry, School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" (CSIC-UAM), Madrid, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
5 shared publicationsMaribel Escoll
Department of Biochemistry, School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" (CSIC-UAM), Madrid, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
5 shared publications- Ana I. Rojo
Department of Biochemistry, Medical College, Autonomous University of Madrid (UAM), Madrid, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Instituto de Investigaciones Biomédicas Sols-Morreale (CSIC-UAM), Madrid, Spain
4 shared publications Eduardo Cazalla
Department of Biochemistry, School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" (CSIC-UAM), Madrid, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
4 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4460
Special Issue “Role of NRF2 Pathway in Chronic Diseases”
The progressive increase in life expectancy over the past century has been accompanied by a parallel rise in the prevalence of chronic diseases, including metabolic, cardiovascular, neurodegenerative, and inflammatory disorders
- 16 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4460
Open AccessSpecial Issue “Role of NRF2 Pathway in Chronic Diseases”
The progressive increase in life expectancy over the past century has been accompanied by a parallel rise in the prevalence of chronic diseases, including metabolic, cardiovascular, neurodegenerative, and inflammatory disorders
- Open Access
- 10 March 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 248, 554-596
Therapeutic potential of isothiocyanates by targeting the NRF2 pathway
- 10 March 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 248, 554-596
Open AccessTherapeutic potential of isothiocyanates by targeting the NRF2 pathway
- Open Access
- 2 March 2026
- Published by Elsevier in Redox Biology
- Vol. 92, 104107
Hexaraphane as a potential therapeutic strategy for tauopathies
- 2 March 2026
- Published by Elsevier in Redox Biology
- Vol. 92, 104107
Open AccessHexaraphane as a potential therapeutic strategy for tauopathies
- Open Access
- 13 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 770
Modulation of the Receptor Tyrosine Kinase TIE2/Tek Pathway by NRF2 Activation in Neurovascular Endothelial Cells
The transcription factor NRF2 orchestrates diverse cellular homeostatic networks, but its role in angiogenesis remains poorly understood. Genetic and pharmacological modulation of NRF2 in mouse neuroendothelial cells altered the expression of several genes involved in endothelial biology. Among these, the TIE2/Tek receptor, essential for vascular development and integrity, was downregulated upon NRF2 activation, accompanied by changes in adherens and tight junction gene expression. Hemin treatment and knockdown revealed that TIE2/Tek repression is independent of the NRF2 repressor BACH1. mRNA stability and ChIP analyses indicated no post-transcriptional or direct transcriptional repression by NRF2. These findings suggest an alternative NRF2-dependent mechanism affecting TIE2/Tek levels and potentially influencing angiogenic regulation.
- 13 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 770
Open AccessModulation of the Receptor Tyrosine Kinase TIE2/Tek Pathway by NRF2 Activation in Neurovascular Endothelial Cells
The transcription factor NRF2 orchestrates diverse cellular homeostatic networks, but its role in angiogenesis remains poorly understood. Genetic and pharmacological modulation of NRF2 in mouse neuroendothelial cells altered the expression of several genes involved in endothelial biology. Among these, the TIE2/Tek receptor, essential for vascular development and integrity, was downregulated upon NRF2 activation, accompanied by changes in adherens and tight junction gene expression. Hemin treatment and knockdown revealed that TIE2/Tek repression is independent of the NRF2 repressor BACH1. mRNA stability and ChIP analyses indicated no post-transcriptional or direct transcriptional repression by NRF2. These findings suggest an alternative NRF2-dependent mechanism affecting TIE2/Tek levels and potentially influencing angiogenic regulation.
- Open Access
- 5 August 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 239, 579-593
Dual targeting of Keap1 and Gsk-3 by hexaraphane in the regulation of transcription factor Nrf2
- 5 August 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 239, 579-593
Open AccessDual targeting of Keap1 and Gsk-3 by hexaraphane in the regulation of transcription factor Nrf2
- Open Access
- 11 July 2025
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 32 (1) , 1-19
A novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy
Background: Non-communicable chronic diseases are characterized by low-grade inflammation and oxidative stress. Extensive research has identified the transcription factor NRF2 as a potential therapeutic target. Current NRF2 activators, designed to inhibit its repressor KEAP1, often exhibit undesirable side effects. As an alternative approach, we previously developed PHAR, a protein–protein interaction inhibitor of β-TrCP1/NRF2, which promotes NRF2 activation. Using the same in silico screening platform, we have now identified a novel compound, P10. This small molecule selectively interferes with the β-TrCP1/NRF2 interaction, leading to NRF2 stabilization and transcriptional activation of its target genes in a β-TrCP1-dependent manner, demonstrating promising effects in a liver model of acute inflammation. Methods: After an in silico screening of ∼1 million compounds, including molecular docking analysis, ADMET evaluation, and molecular dynamics simulations, we identified and characterized a novel small molecule, P10, which inhibits β-TrCP1/NRF2 interaction. The compound was validated using luciferase reporter assays, co-immunoprecipitation, and ubiquitination experiments. The specificity of P10 was assessed by comparing NRF2 signatures in wild-type and Nrf2-null cells. The impact of NRF2 activation induced by P10 was investigated by evaluating its antioxidant and anti-inflammatory responses against tert-butyl hydroperoxide and lipopolysaccharide, respectively. Finally, wild-type and Nrf2-null mice were administered P10 intraperitoneally at a dose of 20 mg/kg daily for five consecutive days. Four hours before sacrifice, all animals received a lipopolysaccharide (LPS) injection at 10 mg/kg. Results: P10 selectively disrupts the interaction between β-TrCP1 and NRF2, thereby inhibiting β-TrCP1-mediated ubiquitination of NRF2 and leading to the upregulation of NRF2 target genes. Additionally, P10 mitigates oxidative stress induced by tert-butyl hydroperoxide and reduces pro-inflammatory markers in an NRF2-dependent manner in macrophages treated with lipopolysaccharide. In a preclinical model of liver inflammation, P10 specifically targets the liver, significantly attenuating lipopolysaccharide-induced inflammation through the activation of NRF2. This is demonstrated by decreased expression of inflammatory cytokine genes and a reduction in F4/80-stained liver macrophages. Notably, this anti-inflammatory effect is absent in Nrf2-knockout mice, confirming its NRF2-dependent mechanism of action. Conclusions: P10 emerges as a promising NRF2 activator by selectively disrupting the β-TrCP1/NRF2 interaction, highlighting its potential as a therapeutic agent for diseases presenting acute liver inflammation. Graphical
- 11 July 2025
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 32 (1) , 1-19
Open AccessA novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy
Background: Non-communicable chronic diseases are characterized by low-grade inflammation and oxidative stress. Extensive research has identified the transcription factor NRF2 as a potential therapeutic target. Current NRF2 activators, designed to inhibit its repressor KEAP1, often exhibit undesirable side effects. As an alternative approach, we previously developed PHAR, a protein–protein interaction inhibitor of β-TrCP1/NRF2, which promotes NRF2 activation. Using the same in silico screening platform, we have now identified a novel compound, P10. This small molecule selectively interferes with the β-TrCP1/NRF2 interaction, leading to NRF2 stabilization and transcriptional activation of its target genes in a β-TrCP1-dependent manner, demonstrating promising effects in a liver model of acute inflammation. Methods: After an in silico screening of ∼1 million compounds, including molecular docking analysis, ADMET evaluation, and molecular dynamics simulations, we identified and characterized a novel small molecule, P10, which inhibits β-TrCP1/NRF2 interaction. The compound was validated using luciferase reporter assays, co-immunoprecipitation, and ubiquitination experiments. The specificity of P10 was assessed by comparing NRF2 signatures in wild-type and Nrf2-null cells. The impact of NRF2 activation induced by P10 was investigated by evaluating its antioxidant and anti-inflammatory responses against tert-butyl hydroperoxide and lipopolysaccharide, respectively. Finally, wild-type and Nrf2-null mice were administered P10 intraperitoneally at a dose of 20 mg/kg daily for five consecutive days. Four hours before sacrifice, all animals received a lipopolysaccharide (LPS) injection at 10 mg/kg. Results: P10 selectively disrupts the interaction between β-TrCP1 and NRF2, thereby inhibiting β-TrCP1-mediated ubiquitination of NRF2 and leading to the upregulation of NRF2 target genes. Additionally, P10 mitigates oxidative stress induced by tert-butyl hydroperoxide and reduces pro-inflammatory markers in an NRF2-dependent manner in macrophages treated with lipopolysaccharide. In a preclinical model of liver inflammation, P10 specifically targets the liver, significantly attenuating lipopolysaccharide-induced inflammation through the activation of NRF2. This is demonstrated by decreased expression of inflammatory cytokine genes and a reduction in F4/80-stained liver macrophages. Notably, this anti-inflammatory effect is absent in Nrf2-knockout mice, confirming its NRF2-dependent mechanism of action. Conclusions: P10 emerges as a promising NRF2 activator by selectively disrupting the β-TrCP1/NRF2 interaction, highlighting its potential as a therapeutic agent for diseases presenting acute liver inflammation. Graphical
- Open Access
- 21 November 2024
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 21 (1) , 1-29
Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier
The Blood-Brain Barrier (BBB) is a complex and dynamic interface that regulates the exchange of molecules and cells between the blood and the central nervous system. It undergoes structural and functional throughout oxidative stress and inflammation, which may compromise its integrity and contribute to the pathogenesis of neurodegenerative diseases. Maintaining BBB integrity is of utmost importance in preventing a wide range of neurological disorders. NRF2 is the main transcription factor that regulates cellular redox balance and inflammation-related gene expression. It has also demonstrated a potential role in regulating tight junction integrity and contributing to the inhibition of ECM remodeling, by reducing the expression of several metalloprotease family members involved in maintaining BBB function. Overall, we review current insights on the role of NRF2 in addressing protection against the effects of BBB dysfunction, discuss its involvement in BBB maintenance in different neuropathological diseases, as well as, some of its potential activators that have been used in vitro and in vivo animal models for preventing barrier dysfunction. Thus, emerging evidence suggests that upregulation of NRF2 and its target genes could suppress oxidative stress, and neuroinflammation, restore BBB integrity, and increase its protection.
- 21 November 2024
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 21 (1) , 1-29
Open AccessRole of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier
The Blood-Brain Barrier (BBB) is a complex and dynamic interface that regulates the exchange of molecules and cells between the blood and the central nervous system. It undergoes structural and functional throughout oxidative stress and inflammation, which may compromise its integrity and contribute to the pathogenesis of neurodegenerative diseases. Maintaining BBB integrity is of utmost importance in preventing a wide range of neurological disorders. NRF2 is the main transcription factor that regulates cellular redox balance and inflammation-related gene expression. It has also demonstrated a potential role in regulating tight junction integrity and contributing to the inhibition of ECM remodeling, by reducing the expression of several metalloprotease family members involved in maintaining BBB function. Overall, we review current insights on the role of NRF2 in addressing protection against the effects of BBB dysfunction, discuss its involvement in BBB maintenance in different neuropathological diseases, as well as, some of its potential activators that have been used in vitro and in vivo animal models for preventing barrier dysfunction. Thus, emerging evidence suggests that upregulation of NRF2 and its target genes could suppress oxidative stress, and neuroinflammation, restore BBB integrity, and increase its protection.
- Open Access
- 3 January 2024
- Published by Elsevier in Redox Biology
- Vol. 69, 103027
Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
- 3 January 2024
- Published by Elsevier in Redox Biology
- Vol. 69, 103027
Open AccessSpecific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
- Open Access
- 31 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12280
Mechanisms of NURR1 Regulation: Consequences for Its Biological Activity and Involvement in Pathology
NURR1 (Nuclear receptor-related 1 protein or NR4A2) is a nuclear protein receptor transcription factor with an essential role in the development, regulation, and maintenance of dopaminergic neurons and mediates the response to stressful stimuli during the perinatal period in mammalian brain development. The dysregulation of NURR1 activity may play a role in various diseases, including the onset and progression of neurodegenerative diseases, and several other pathologies. NURR1 is regulated by multiple mechanisms, among which phosphorylation by kinases or SUMOylation are the best characterized. Both post-translational modifications can regulate the activity of NURR1, affecting its stability and transcriptional activity. Other non-post-translational regulatory mechanisms include changes in its subcellular distribution or interaction with other protein partners by heterodimerization, also affecting its transcription activity. Here, we summarize the currently known regulatory mechanisms of NURR1 and provide a brief overview of its participation in pathological alterations.
- 31 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12280
Open AccessMechanisms of NURR1 Regulation: Consequences for Its Biological Activity and Involvement in Pathology
NURR1 (Nuclear receptor-related 1 protein or NR4A2) is a nuclear protein receptor transcription factor with an essential role in the development, regulation, and maintenance of dopaminergic neurons and mediates the response to stressful stimuli during the perinatal period in mammalian brain development. The dysregulation of NURR1 activity may play a role in various diseases, including the onset and progression of neurodegenerative diseases, and several other pathologies. NURR1 is regulated by multiple mechanisms, among which phosphorylation by kinases or SUMOylation are the best characterized. Both post-translational modifications can regulate the activity of NURR1, affecting its stability and transcriptional activity. Other non-post-translational regulatory mechanisms include changes in its subcellular distribution or interaction with other protein partners by heterodimerization, also affecting its transcription activity. Here, we summarize the currently known regulatory mechanisms of NURR1 and provide a brief overview of its participation in pathological alterations.
- Open Access
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 16-17
Transcription factor NRF2 regulates the permeability of the blood brain barrier at the level of ANGPT1/2-TIE2 signaling
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 16-17
Open AccessTranscription factor NRF2 regulates the permeability of the blood brain barrier at the level of ANGPT1/2-TIE2 signaling